rheumatoid arthritis - Nursing Case Study

Pathophysiology

• Primary mechanism: Rheumatoid arthritis (RA) is primarily driven by an autoimmune response where the immune system mistakenly targets the synovial membrane, leading to chronic inflammation. This inflammation results in synovial hyperplasia and pannus formation, which progressively damages joint structures.

• Secondary mechanism: The recruitment and activation of immune cells, such as T-cells and B-cells, in the synovial tissue lead to the production of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1, IL-6). These cytokines perpetuate the inflammatory cycle, causing further joint destruction and systemic symptoms.

• Key complication: Persistent inflammation can result in joint deformity and loss of function due to cartilage degradation and bone erosion. Additionally, systemic involvement can lead to complications such as cardiovascular disease and increased risk of infections.

Patient Profile

Demographics:

54-year-old female, office worker

History:

• Key past medical history: Diagnosed with rheumatoid arthritis 5 years ago, hypertension, type 2 diabetes

• Current medications: Methotrexate, prednisone, metformin, lisinopril

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing joint pain and swelling in hands and knees

• Key symptoms: Morning stiffness lasting over an hour, fatigue, mild fever, difficulty performing daily tasks

• Vital signs: Blood pressure 148/92 mmHg, heart rate 98 bpm, respiratory rate 20 breaths per minute, temperature 100.2°F

Section 1

As the clinical team continued to monitor the patient, new complications began to emerge. The patient reported increased fatigue and shortness of breath, which prompted further investigation. During the assessment, the nurse noted slight cyanosis in the patient's lips and peripheral extremities. On auscultation, there were mild crackles at the lung bases, suggesting potential fluid overload or pulmonary involvement. The patient's vital signs showed a notable change: blood pressure had risen to 158/96 mmHg, indicating worsening hypertension, and her heart rate was now 104 bpm, reflecting possible compensatory tachycardia.

Laboratory tests were ordered to delve deeper into the patient's condition. The results revealed elevated inflammatory markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), consistent with the active inflammatory process. Additionally, a chest X-ray indicated mild pleural effusion, which could be attributed to the inflammatory nature of rheumatoid arthritis or a side effect of the medications, particularly methotrexate. Renal function was slightly impaired, with the serum creatinine level creeping upward, necessitating a careful review of the patient's medication regimen, especially given her history of hypertension and diabetes.

The new complications indicated systemic involvement of rheumatoid arthritis, likely exacerbated by both the disease's progression and the side effects of long-term treatment. The clinical team needed to reevaluate the patient's management plan, considering potential adjustments to her medication to better control inflammation and mitigate cardiovascular risks. This situation called for an interdisciplinary approach, incorporating the expertise of rheumatology, cardiology, and nephrology, to optimize the patient's treatment and prevent further deterioration.

Section 2

As the clinical team continued to navigate the complexities of the patient's condition, they focused on the new diagnostic results to guide their next steps. The recent findings of mild pleural effusion and impaired renal function prompted further evaluation through a comprehensive metabolic panel and a renal ultrasound. The metabolic panel showed elevated blood urea nitrogen (BUN) at 28 mg/dL and worsening creatinine levels at 1.8 mg/dL, indicating a decline in renal function likely exacerbated by the patient's existing hypertension and diabetes. The renal ultrasound revealed no significant structural abnormalities, suggesting that the impaired function might be due to the combined effects of medication, disease progression, and vascular complications.

Given these diagnostic insights, the interdisciplinary team convened to reassess the patient's medication regimen. The risk of methotrexate-induced renal impairment was considered, leading to a discussion about reducing the dosage or switching to an alternative disease-modifying antirheumatic drug (DMARD). Additionally, the team deliberated on the need for tighter control of the patient's blood pressure and blood sugar levels to prevent further renal damage. A cardiology consult recommended the initiation of an angiotensin-converting enzyme (ACE) inhibitor to address hypertension and provide renal protection, while a nephrology consult suggested careful monitoring of renal function with the introduction of any new medication.

The team also recognized the need for enhanced management of the patient's inflammatory state. Given the elevated CRP and ESR levels, an adjustment in her anti-inflammatory treatment was necessary to prevent further systemic involvement and alleviate symptoms. Meanwhile, continued monitoring of the patient's respiratory status was crucial, as the mild crackles and pleural effusion warranted vigilance for potential progression to more significant pulmonary issues. This comprehensive approach, integrating insights from multiple specialties, aimed to stabilize the patient's condition and preempt further complications, setting the stage for future reassessments and adjustments in her care plan.

Section 3

As the clinical team implemented the revised care plan, they closely monitored the patient's response to the adjusted medication regimen and supportive therapies. Within a week, the patient exhibited signs of improved blood pressure control, with readings consistently averaging 128/78 mmHg, following the initiation of the ACE inhibitor. This positive change was accompanied by a slight decrease in blood sugar levels, with fasting glucose readings now ranging between 110-120 mg/dL, suggesting a potentially beneficial impact on her renal function. However, the ongoing concern was the patient's renal status, which remained precarious. Repeat tests showed a BUN level of 26 mg/dL and a creatinine level of 1.7 mg/dL, indicating only marginal improvement.

Despite these initial positive responses, the patient began to experience increased joint stiffness and pain, particularly in her hands and wrists, suggesting inadequate control of her rheumatoid arthritis symptoms. The interdisciplinary team, aware of the need to balance renal protection with effective management of her inflammatory state, opted to introduce hydroxychloroquine as an adjunct therapy to methotrexate, while cautiously tapering the methotrexate dose to minimize nephrotoxicity. This decision was made after thorough discussion and agreement on the importance of maintaining her quality of life through better symptom management.

Meanwhile, the mild pleural effusion had not progressed significantly, with the patient's respiratory assessment remaining stable. Her oxygen saturation levels were consistently above 94% on room air, and she reported no shortness of breath or increased cough. Regular follow-up with pulmonary function tests was scheduled to ensure early detection of any potential pulmonary complications. The team's integrated approach, emphasizing proactive monitoring and dynamic treatment adjustments, set the stage for ongoing evaluation and refinement of the patient's comprehensive care plan, as they remained vigilant for any new complications or changes in her condition.

Section 4

As the care team continued to monitor the patient, they noted a concerning change in her status during a routine follow-up. The patient reported increased fatigue and a noticeable reduction in her ability to perform daily activities due to worsened joint pain and swelling. Upon physical examination, the clinical team observed significant synovitis in the small joints of her hands, with a notable increase in tenderness and limited range of motion compared to previous assessments. Her grip strength was markedly reduced, impacting her ability to manage tasks independently. These findings suggested that despite the recent introduction of hydroxychloroquine, her rheumatoid arthritis was not adequately controlled.

In response, the team ordered additional diagnostic tests to further elucidate the underlying cause of her worsening symptoms. Laboratory results revealed an elevated erythrocyte sedimentation rate (ESR) of 47 mm/hr and a C-reactive protein (CRP) level of 20 mg/L, both indicative of heightened inflammatory activity. Moreover, her rheumatoid factor remained elevated. Given these findings, the team suspected that the current medication adjustments were insufficient to manage her disease activity effectively. This prompted a reassessment of her entire medication regimen and consideration of additional disease-modifying antirheumatic drugs (DMARDs) or biologics, weighing the potential renal implications of such interventions.

Recognizing the need for a more aggressive approach while still safeguarding her renal function, the interdisciplinary team engaged in a collaborative discussion. They decided to consult with a rheumatologist to explore the possibility of introducing a biologic agent, such as a TNF inhibitor, to better control her rheumatoid arthritis. The team also emphasized the importance of patient education, ensuring she understood the rationale behind the proposed changes and the need for close monitoring of her renal function and inflammatory markers. This collaborative and patient-centered strategy aimed to optimize her quality of life while minimizing the risk of further complications, setting a clear path for the next steps in her care journey.

Section 5

Several weeks after the introduction of the TNF inhibitor, the patient returned for a follow-up appointment. She reported some improvement in joint pain and swelling, but still experienced persistent fatigue, which was now accompanied by new, intermittent episodes of shortness of breath and palpitations. Concerned by these symptoms, the care team conducted a physical examination and noted mild tachycardia with a heart rate of 102 beats per minute. Her blood pressure was stable at 125/78 mmHg, and her respiratory rate was slightly elevated at 22 breaths per minute. On auscultation, there were no significant abnormalities in lung sounds, and her oxygen saturation was 94% on room air. These findings prompted the team to investigate whether her symptoms could be related to the recent medication change or an emerging complication.

The team ordered additional laboratory tests and an ECG to further evaluate her cardiovascular status. The ECG showed a sinus tachycardia without any acute ischemic changes. However, laboratory tests revealed a hemoglobin level of 9.8 g/dL, suggesting mild anemia, which could potentially explain her fatigue and palpitations. A ferritin level was also checked and was consistent with iron deficiency anemia. This finding led the team to consider whether her rheumatoid arthritis or the TNF inhibitor might be contributing to gastrointestinal blood loss or malabsorption.

In response, the care team initiated an iron supplementation regimen while planning for further investigation into the cause of her anemia, including a referral to a gastroenterologist. They also reinforced the importance of ongoing monitoring of her inflammatory markers and renal function, given the need for continued use of a TNF inhibitor. The team emphasized a holistic approach, including dietary advice and regular follow-up, to address both her rheumatoid arthritis and the newly identified anemia, thereby striving to improve her overall health and quality of life.